Canine Atopic Dermatitis Market Report 2025

The canine atopic dermatitis market size has grown rapidly in recent years. It will grow from $2.49 billion in 2024 to $2.76 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to a rise in pet ownership, increased awareness of pet health, a growing incidence of allergic conditions in dogs, higher spending on veterinary healthcare, and the expanding availability of pet insurance.

The canine atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $4.09 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth during the forecast period can be attributed to the increasing adoption of telemedicine in veterinary care, rising demand for personalized pet treatments, growing investments in veterinary research and development, the expanding trend of pet humanization, and the increased use of artificial intelligence in veterinary diagnostics. Key trends expected in the forecast period include advancements in monoclonal antibody therapies, the application of artificial intelligence in diagnostic tools, integration of telemedicine for dermatological care, the use of wearable devices for tracking symptoms, progress in allergen-specific immunotherapy, and the development of mobile applications for monitoring treatment.

The growing number of skin allergy cases in dogs is expected to drive the expansion of the canine atopic dermatitis market. Skin allergies in dogs occur when their immune system overreacts to allergens like pollen, certain foods, or flea bites, leading to symptoms such as itching, redness, and irritation. This increase is partly due to greater exposure to environmental pollutants and allergens, which can trigger intensified immune responses and cause skin discomfort. Treatments for canine atopic dermatitis help alleviate these issues by minimizing inflammation and itching, as well as preventing secondary infections, thereby improving dogs' skin health and comfort. For example, in January 2024, the National Institutes of Health (NIH), a US-based government agency, reported that 7,915 dog owners (28.7%) indicated their dogs had experienced skin-related conditions. The data showed a steady increase in skin issues with age, from 7% in puppies to 37% in senior dogs. This rising prevalence is contributing to the growth of the canine atopic dermatitis market.

The increase in pet ownership is also contributing to the growth of the canine atopic dermatitis market. Pet ownership involves caring for domesticated animals, such as dogs, cats, and other companions, within a household setting. A key driver of this trend is the growing humanization of pets, where animals are increasingly seen as family members and sources of emotional support and companionship. Addressing canine atopic dermatitis plays an essential role in improving pets' lives by easing chronic itching and inflammation, enhancing skin health, and boosting overall comfort and well-being. For instance, in April 2025, the American Pet Products Association (APPA), a US-based trade association, reported that 94 million US households (71%) owned a pet, up from 86.9 million households (66%) in 2023-2024. As a result, the increase in pet ownership is fueling demand in the canine atopic dermatitis market.

Leading companies in the canine atopic dermatitis market are pursuing regulatory approvals to expand the global reach and availability of their treatments. Regulatory approvals are formal authorizations granted by health authorities after verifying that medical products meet safety, efficacy, and quality standards through comprehensive testing. For example, in September 2024, Elanco Animal Health Inc., a US-based pharmaceutical company focused on animal health, received US FDA approval for Zenrelia, a once-daily oral JAK inhibitor designed to treat allergic and atopic dermatitis in dogs. Zenrelia represents a significant innovation by addressing chronic, acute, or seasonal itching and inflammation with a single daily tablet. It functions by targeting the source of the itch and blocking the signaling pathways responsible for allergic reactions, thereby breaking the itch-scratch cycle. The treatment provides noticeable improvement from the first dose and helps minimize rebound itching, which is a common drawback in dogs treated with competing JAK inhibitors.

Major players in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill’s Pet Nutrition Inc., IDEXX Laboratories Inc., Royal Canin SAS, Ceva Santé Animale S.A., Boragen, Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Antech Diagnostics Inc., Vetoquinol S.A., Heska Corporation, Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Bioceltix S.A., Nextmune AB, OKAVA Pharmaceuticals Inc.

North America was the largest region in the canine atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in canine atopic dermatitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the canine atopic dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The canine atopic dermatitis market consists of sales of products including medicated shampoos, hypoallergenic diets, omega-3 fatty acid supplements, skin barrier repair creams, and topical antimicrobial or antifungal treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The rapid escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are significantly impacting the veterinary healthcare sector, particularly in the supply of pharmaceuticals, medical devices, and animal care equipment. Higher duties on imported veterinary drugs, diagnostic tools, surgical instruments, and pet care products have increased operational costs for veterinary clinics, animal hospitals, and livestock care providers, forcing them to raise service fees or absorb shrinking margins. Livestock and agricultural sectors face similar challenges, with tariffs on feed additives, vaccines, and breeding equipment driving up production costs and affecting animal health management. Additionally, retaliatory tariffs in key export markets have reduced demand for U.S.-produced veterinary products, further straining industry revenues. The sector must now prioritize local sourcing, preventive care solutions, and digital health innovations to mitigate rising costs while maintaining high standards of animal care.

The canine atopic dermatitis market research report is one of a series of new reports that provides canine atopic dermatitis market statistics, including canine atopic dermatitis industry global market size, regional shares, competitors with a canine atopic dermatitis market share, detailed canine atopic dermatitis market segments, market trends and opportunities, and any further data you may need to thrive in the canine atopic dermatitis industry. The canine atopic dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Canine atopic dermatitis is a long-term, inflammatory skin disorder in dogs triggered by allergic reactions to environmental allergens like pollen, dust mites, mold, or certain foods. It is a hereditary condition that results in severe itching, skin redness, and frequent skin infections. The main goal of treating canine atopic dermatitis is to alleviate itching, decrease inflammation, and control secondary infections to enhance the dog’s overall well-being.

The primary product categories used in the management of canine atopic dermatitis include glucocorticoids, antihistamines, immunosuppressants, monoclonal antibodies (mAbs), and other related therapies. Glucocorticoids are synthetic, broad-acting hormones that effectively relieve itching and inflammation by suppressing the immune response. This condition affects a variety of dog breeds, including German Shepherds, Terriers, Retrievers, and others, with common indications such as ectoparasites, food allergies, and allergic skin infections. Treatment methods include oral, topical, and injectable routes, and these products are distributed through veterinary clinics, retail pharmacies, online pharmacies, and other distribution channels.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.